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Abstract 17 
The need for governments to encourage antibiotic development is widely 18 
agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be 19 
spread widely – which is unlikely given the $1 billion sums proposed– we 20 
should be wary, for this approach is likely to evolve into one of picking, or 21 
commissioning, a few ‘winners’ based on extrapolation of current resistance 22 
trends. The hazard to this is that, whilst the evolution of resistance has 23 
predictable components, notably mutation, it also has completely 24 
unpredictable ones, contingent upon “Black Swan” events. These include the 25 
‘escape’ of ‘new’ resistance genes from environmental bacteria and the 26 
recruitment of these genes by promiscuous mobile elements and epidemic 27 
strains. Such events can change the resistance landscape rapidly and 28 
unexpectedly, as with the rise of Escherichia coli ST131 with CTX-M-ESBLs 29 
and the emergence of ‘impossible’ vancomycin-resistant enterococci. Given 30 
such unpredictability, we simply cannot say with any certainty, for example, 31 
which of four current approaches to combatting metallo--lactamases (MBLs) 32 
offers the best prospect of sustainable, prizeworthy, success. Only time will 33 
tell, though it is encouraging is that multiple potential approaches to 34 
overcoming these problematic enzymes are being pursued. Rather than 35 
seeking to pick winners, governments should aim to reduce development 36 
barriers, as with recent relaxation of trial regulations. In particular, once -37 
lactamase inhibitors have been successfully trialled with one partner, there is 38 
scope to facilitate licensing them for partnering with other established -39 
lactams, thereby insuring against new emerging resistance.  40 
  41 
Introduction: growing resistance and declining antibiotic 42 
development 43 
Recent years have seen a dramatic proliferation of gram-negative 44 
opportunistic pathogens resistant to multiple antibiotics, including 45 
carbapenems. In countries where these bacteria are most prevalent, notably 46 
India, it is common practice to administer colistin empirically to patients with 47 
severe infections.1 Even in less-affected countries, carbapenems are 48 
increasingly being employed for empirical therapy, leaving little left in reserve. 49 
In the community, resistance has complicated the treatment of infections as 50 
diverse as cystitis,2 typhoid,3 gonorrhoea4 and tuberculosis.5 Simultaneously, 51 
the flow of new antibiotics has faltered for reasons that have been well 52 
rehearsed.6 Two of these are paramount. First, there is the problem of finding 53 
drugs that can enter Gram-negative bacteria and evade efflux.7,8 Secondly, 54 
regulatory requirements have grown over time, increasing the cost and 55 
complexity of clinical trials.9,10 This latter change particularly impacts the 56 
ultimate revenue return from antibiotics, as they are only given briefly and 57 
their use is being increasingly restricted, limiting sales of new agents.6,11 Not 58 
surprisingly, several major pharmaceutical companies have quit the field 59 
altogether, while others were lost to mergers and takeovers. 60 
This combination of growing resistance and a dwindling pipeline threatens our 61 
future ability to treat infection, giving ample reason to fear for the future 62 
viability of intensive care and transplant medicine, and even to manage some 63 
long-controlled community infections. 64 
Responding to the challenge 65 
Infection control, which reduces the need to use antibiotics, with their 66 
contingent selection pressure, is vital to containing resistance. Stewardship is 67 
crucial too, though it is easier to describe bad stewardship than to define 68 
optimal usage diversity and treatment duration.12 Many of us believe that 69 
stewardship must advance from its present model, predicated on resistance 70 
epidemiology and risk assessment, to individualised treatment informed by 71 
rapid diagnostics,13,14 But the deployment of these diagnostics is slow and the 72 
current pace of microbiology remains little changed since the 1950s, typically 73 
taking two days to complete: one day to grow the bacteria and another to test 74 
resistance, with the patient being treated empirically in the interim. Mass 75 
spectroscopy has accelerated identification, but not susceptibility testing. 76 
Against this background, new antibiotics will be needed, and the UK 77 
Government’s O’Neill Review,15 the WHO16 and US Pew Trust17 all argue that 78 
governments and international agencies should seek to encourage and 79 
reinvigorate work in the field. Two types of incentive are proposed and, to 80 
some degree, deployed: Push and Pull.18,19 ‘Push’ provides early finance, 81 
typically small-scale, to support discovery and early development. The 82 
challenge is in then raising the capital to progress whatever discoveries are 83 
made. Pull incentives aim to reward the developers of valuable new agents, 84 
and potentially involve much larger sums. Most radically, it is proposed to give 85 
prizes. Thus, O’Neill,15 argues for “market entry rewards” of c. $1 billion for 86 
the successful production of new antibiotics, to be funded from a percentage 87 
of G20 countries’ existing healthcare spending”. Such a policy, presently 88 
under discussion, requires a ‘picking of winners’ and, as e.g. with military 89 
aircraft, seems liable, if adopted, to evolve into a commissioned development 90 
model.  91 
Predicting the future 92 
Picking winners requires prediction of the future. In science we habitually do 93 
this by extrapolating from past trends. When I am phoned by market 94 
forecasters, venture capitalists or stockbrokers, seeking my views on the 95 
future of resistance, the easiest response is to look at the growing tally of 96 
carbapenemase producers and to extend the line. Sometimes their questions 97 
are leading: ‘Will Klebsiella with carbapenemases will spread like ESBL 98 
producers?’ ‘What about Escherichia coli?’ ‘Will carbapenemase-producing 99 
Klebsiella in the UK, France and Germany will reach the 30% seen in Italy?’ 100 
‘When?’ Here the easy answer is to recall that resistance accumulates more 101 
slowly in northern Europe than southern and to adjust time frames 102 
accordingly. 103 
Modelling by governments and international agencies15-17,20 is more 104 
sophisticated but still depends on extrapolating from past trends. O’Neill15 105 
goes so far as to predict resistance rates, along with contingent mortality and 106 
costs in 2050, a third of a century ahead, based on analyses by the 107 
accountancy and consulting firms, KPMG and RAND. I can now guarantee to 108 
see a slide with these projections at every resistance congress I attend.  109 
Is the future predictable? 110 
Is the long-term future so knowable? A simple game is to divide the past 210 111 
years, from 1800, into decades and ask if the landscape of Europe at the end 112 
of each period was predictable at its start. For 1800 and 1810, with 113 
Napoleon’s wars raging, the answer is unequivocally ‘No’, as also for 1910, 114 
1930, 1940 and 1980. For other decades the answer is a qualified ‘Yes’, 115 
giving a predictable: unpredictable ratio of 15:6. These aren’t brilliant odds 116 
and, if one plays 33-year periods, and worldwide, they become much worse. 117 
Or consider financial markets, whose history is strewn with the ruin of those 118 
who assumed trends would persist. Long Term Capital Management is a 119 
recent classic:21 a hedge fund whose principals included two Nobel 120 
Laureates. Its rationale was that brief recurrent pricing anomalies between 121 
long- and short- maturity bonds could be identified by computer programs and 122 
then profitably ‘arbitraged.’ Effectively, the fund bought whichever bond 123 
maturity seemed under-priced and simultaneously short-sold whichever 124 
seemed over-priced, waited for the anomaly to unwind, then closed both 125 
positions and took the profit.   Because these anomalies were tiny, investors’ 126 
funds had to be ‘geared’ by considerable borrowing. From 1994 to 1998, the 127 
approach succeeded, yielding 30-fold greater profits than simply holding US 128 
Treasury Bonds long term, but then failed catastrophically, losing $120 billion 129 
when the Asian financial crisis struck, changing the pricing of risk. 130 
The point – famously highlighted by Nassim Taleb22 – is that seemingly stable 131 
trends are more vulnerable than we suppose to sudden reversal owing to 132 
‘Black Swan’ events, and, crucially, that history hinges on these Black Swans 133 
as much as on the periods of steady progress.  ‘Black Swan’, in context, 134 
means an unexpected and impactful event.  The Roman satirist Juvenal wrote 135 
of something being "rara avis in terris nigroque simillima cygno" ("A rare bird 136 
in these lands and very much like a black swan"), suggesting impossibility. 137 
Fourteen hundred years later, in sixteenth century London, ‘Black Swan’ was 138 
a byword for the implausible, as with ‘flying pigs’ nowadays. Then the early 139 
European explorers of Australia found that their notion that ‘All swans are 140 
white’ was mistaken…  The likelihood of any one Black Swan event is tiny but 141 
the number of possible Black Swans events is large. Thus, in any activity 142 
involving uncertainty, occasional bird-strikes –some of them heavy– become 143 
inevitable. Donald Rumsfeld was derided for talking of ‘Unknown 144 
Unknowns’,23 but captures the point: long-term planning is most vulnerable to 145 
what we do not anticipate. 146 
Black Swan events in the evolution of resistance 147 
Antibiotic usage is undoubtedly the driver of accumulating resistance. But use 148 
does not cause the initial emergence of resistance. An antibiotic that ‘caused’ 149 
resistance would be a mutagen and would be denied a license. Rather, 150 
resistance originates by random processes – mutation and the acquisition of 151 
resistance genes mobilised from the chromosomes of other bacteria. We can 152 
predict mutation risk to some degree by in vitro experiments, and agents that 153 
readily select resistant mutants in vitro generally do so in patients too, 154 
meaning that they are best avoided as monotherapy.24 Examples include 155 
fusidic acid and streptomycin for all species, oxyimino cephalosporins (e.g. 156 
cefotaxime, ceftazidime and ceftriaxone) for AmpC-inducible 157 
Enterobacteriaceae25,26 and imipenem for Pseudomonas aeruginosa.27 More 158 
generally, it is ‘brave’ (meaning ‘high risk’.) to develop any agent where the 159 
mutation frequency against multiple target pathogens exceeds 10-8, even if in 160 
vitro studies suggest that the mutants are ‘unfit’.28 It is possible, along these 161 
lines, to foresee threats to recently-licensed anti-gram-negative agents. 162 
Ceftazidime/avibactam is vulnerable to KPC mutants with increased affinity for 163 
ceftazidime. Such mutants can easily be obtained in vitro29 and were selected 164 
in 3/31 KPC K. pneumoniae patients treated with ceftazidime/avibactam in 165 
Pittsburgh.30 For ceftolozane/tazobactam there are reports of in vivo selection 166 
of Pseudomonas aeruginosa mutants with sequence mutations AmpC also 167 
conferring ceftazidime/avibactam resistance.31,32  168 
No such simple predictor can be applied to gene escapes, for we have no way 169 
of knowing what gene will escape, when it will do so, nor which organisms it 170 
will reach. Such escapes are Black Swan events, and Table 1 lists important 171 
past examples and sources.33-35 Note that we remain ignorant of the origins of 172 
many now widely dispersed and impactful genes, including blaTEM. Our 173 
ignorance also extends to predicting how extensively an escaped gene will 174 
spread. blaTEM-1 has been vastly more successful than blaTEM-2, though both 175 
have been in circulation for similarly long periods36 and may be post-escape 176 
mutants of one another. It is likely that blaTEM-1’s success is because it is 177 
carried by Tn3, which spreads efficiently among plasmids.37,38 If so, its 178 
recruitment by this transposon was another Black Swan event, not (yet) 179 
replicated by blaTEM-2.  180 
Then there is the issue of which bacterial strains acquire escaped genes and 181 
whether these have epidemic potential. It is useful here to consider the 182 
trajectory of oxyimino cephalosporin resistance in Escherichia coli, illustrated 183 
in Figure 1.39 During the 1990s this rate remained trivial, at 1-2% in the UK, 184 
despite selective oxyimino-cephalosporins being heavily used.40 At the start of 185 
the 1990s c. 50% of E. coli isolates carried blaTEM-1,41 so it would have been 186 
reasonable to expect a steady cephalosporin-driven accumulation of isolates 187 
with blaTEM-ESBL variants in the gut flora. Yet, this did not occur and the 188 
cephalosporin resistance rate for E. coli was no higher in 2000 than in 1990. 189 
This rate only rose after 2002, with the conjunction of two Black Swan events: 190 
first the escape of blaCTX-M genes from the chromosomes of Kluyvera spp. to 191 
(principally) IncFII plasmids42 and, secondly, the acquisition of these plasmids 192 
by fluoroquinolone-resistant variants of E. coli ST131, a lineage with epidemic 193 
potential.43 ST131 isolates with CTX-M ESBLs now account for the majority of 194 
ESBL E. coli infections.43,44 Nothing before 2000 predicted the changes seen 195 
after 2002 and no one, looking the 2002-6 trajectory alone, would suppose it 196 
was preceded by a long period when another type of ESBL failed to 197 
accumulate.  198 
There is a further trap. We look back on the past, knowing what did happen 199 
and seek to rationalise it, creating a prism where the events that occurred 200 
begin to look inevitable. The trigger for the First World War was Gabriel 201 
Principe’s slaying of the Austrian Crown Prince and his wife on June 28th 202 
1914, initiating a cascade of events leading to the start of a general war in 203 
early August.45 It is easy to follow the grim logic of the chain reaction and to 204 
forget that the trigger was a Black Swan event. Principe could only shoot the 205 
Prince because the latter’s motorcade took a wrong turning and, realising the 206 
mistake, stopped next to him, giving a bad shot an easy target. Had this not 207 
happened, the powder trail would have remained unlit, though it might have 208 
been ignited by another event, or maybe not. 209 
Similarly with resistance. We know what genes have escaped and 210 
proliferated; considerable molecular research is undertaken to explain how 211 
they escaped and proliferated. But we do not know what other genes might 212 
have escaped but have not yet done so, nor if, and when, they will do so in 213 
the future. Consequently, it is naïve to model the future trajectory of 214 
carbapenem resistance on present trends for OXA-48, KPC, VIM, IMP and 215 
NDM when, next year, the blaB carbapenemase gene of Chryseobacterium 216 
meningosepticum (say) may escape, perhaps achieving the same differential 217 
in success that blaCTX-M achieved relative to blaTEM-ESBL. The fact that there are 218 
more genes that could escape is well illustrated by the work of D’Costa et al., 219 
who found soil streptomycetes – a common source of escaped genes (Table 220 
1) – that could hydrolyse daptomycin or glycosylate telithromycin, 221 
compromising activity.46,47  222 
What is more, we trap ourselves into thinking that the types of resistance that 223 
will escape in the future will resemble those that spread previously, when this 224 
need not be so. For 30 years we thought of aminoglycoside resistance as 225 
being due to aminoglycoside-modifying enzymes, and pharmaceutical 226 
companies remodelled aminoglycosides to evade acetylation, phosphorylation 227 
or nucleotidylation.48 But then we discovered other escaped genes – armA 228 
and rmt– could methylate the ribosomal RNA to block the binding of all 229 
systemic three-ring aminoglycosides.49  230 
Perhaps the most unexpected Black Swan event was the escape of the 231 
VanHAXY operon to Tn1546, putatively from Paenibacillus spp.50,51 This 232 
provided a complete system to replace normal peptidoglycan precursors, 233 
conferring vancomycin resistance in the enterococci that acquired the 234 
transposon. This should be a salutary lesson, illustrating that what is possible 235 
in resistance extends beyond what seems reasonably predictable. In the early 236 
years of my career I taught – as did many others – that ‘Vancomycin 237 
resistance is impossible because it binds to a fundamental cell wall substrate, 238 
conserved across bacteria….’ Quite wrong, as it turned out. 239 
Future Black Swan events may take a similarly unexpected form. Instead of a 240 
new MBL escaping from C. meningosepticum (say), envisage instead a 241 
plasmid-borne -lactam-resistant PBP3 spreading among Gram-negative 242 
bacteria. This would be akin to mecA-mediated resistance in MRSA.52 243 
Crucially, it would reduce susceptibility to almost all anti-Gram-negative -244 
lactams and inhibitor combinations; all that would wholly escape would be the 245 
few analogues that primarily target other PBPs – ampicillin, cephaloridine, 246 
imipenem and mecillinam.53,54  247 
Put simply, the future of resistance, over the coming third of a century, is as 248 
unknowable to us as were the coming 33 years – up to the end of the Second 249 
World War – were to those late Edwardians who, looking back over a century 250 
of steady progress, confidently boarded Titanic in April 1912. As Lawrence 251 
Beesley, who survived that sinking, wrote: 252 
 “It seems to me that the disaster about to occur was the event that not only 253 
made the world rub its eyes and awake but woke it with a start, keeping it 254 
moving at a rapidly accelerating pace ….” 55 255 
What can be done to prepare? 256 
The fact that future Black Swan events are unknowable is not a counsel of 257 
despair. It does not mean that no preparations can be made. But it is a 258 
counsel of humility and does have a bearing on which preparations are 259 
appropriate. Crucially, it argues that we should admit ignorance and spread 260 
risk, rather than concentrate effort and rewards on a few anticipated ‘winners’. 261 
 Suppose a system of G20 (or whatever) prizes had been in place in the 262 
1980s during the last flurry of anti-Gram-negative development? Which -263 
lactam should have been rewarded? Cefotaxime, as first up, with 10-100-fold 264 
lower MICs for Enterobacteriaceae than earlier cephalosporins? Ceftazidime, 265 
for including Pseudomonas aeruginosa in its spectrum of activity? Imipenem, 266 
for its ability to bypass cephalosporin-hydrolysing AmpC and ESBL enzymes? 267 
Aztreonam, for evading MBLs? Hindsight suggests answers that were not 268 
evident at the time. ESBLs – now seen as the main Achilles Heel of the 269 
cephalosporins – only became a significant issue late in the 1980s,56 around 4 270 
years after imipenem was launched and 7-8 years after cefotaxime. The first 271 
acquired MBL was not described until 1991,57 and none was a major problem 272 
until NDM-1 from 2007/8.58 An aztreonam-inhibitor combination (to protect 273 
against co-produced ESBLs) was only proposed in 2011.59 What is important, 274 
surely, is not whether imipenem and aztreonam were prizeworthy in the 275 
1980s. Rather, it is that they were ready and waiting when they were needed. 276 
Just as were vancomycin and colistin, many years after they were first 277 
launched… 278 
Which brings us back to the present. Table 2 lists developmental -lactams 279 
active against MBL producers.60-67 These fall into four broad groups: (i) MBL-280 
stable monobactams protected against co-produced ESBLs and AmpC -281 
lactamases with inhibitors (ii) MBL-labile -lactams combined with triple-action 282 
diazabicyclooctanes; (iii) -lactams combined with MBL-inhibiting boronates 283 
and (iv) MBL-stable -lactams. All have in vitro activity against most MBL 284 
producers, but each carries limitations and/or uncertainties. Which should be 285 
rewarded? One? All? The first to market? The truth is that we do not know 286 
which approach is best even in the short term, let alone which will best avoid 287 
falling victim to future Black Swan events. Rather than trying to pick a winner 288 
among these approaches, we should be heartened that a diversity of options 289 
are progressing, and should encourage this, for it increases our odds of 290 
keeping ahead. 291 
Encouraging diversity in development 292 
How best to encourage this diversity in drug development? The answer must 293 
lie in reducing cost and barriers to entry, for surely the G20 cannot commit to 294 
offering $1 billion to every hopeful molecule that successfully passes clinical 295 
trials? (Which is exactly the reason why the rewards model would likely evolve 296 
into one of commissioned development of expected ‘winners’).  297 
There are some encouraging developments. Historically, antibiotics required 298 
two Phase III trials per indication, showing non-inferiority to a ‘standard-of-299 
care’ comparator.68 Such trials model empirical usage and are 300 
unrepresentative when, in most of the developed world, stewardship 301 
reasonably demands that new agents are reserved for microbiologically-302 
directed treatment of infections caused by multiresistant pathogens. Anyone 303 
doubting the wastage of this traditional antibiotic-development pathway should 304 
consider ceftazidime/avibactam. Some 81-86% of the patients included in the 305 
two pivotal Phase III studies so far published had ceftazidime-susceptible 306 
pathogens.69,70 For these individuals, whose recruitment cost its sponsor 307 
roughly $100,000 per patient, the trials assessed only the safety of avibactam, 308 
not its efficacy against relevant -lactamases (though this was convincingly 309 
demonstrated elsewhere71). The deficiencies of this expensive and wasteful 310 
approach are now being rectified to a degree: meropenem-vaborbactam was 311 
licensed by the FDA on the basis of one sizeable Phase III complicated 312 
urinary tract infection trial together with a resistant pathogens trial, 313 
representing multiple infection types. This approach should deliver relevant 314 
information less expensively, thereby lowering barriers to entry. However, 315 
more radical approaches are needed, at least for -lactamase inhibitors, 316 
which represent one of the main areas of current development. Early 317 
combinations – amoxicillin/clavulanate, ampicillin/sulbactam and 318 
piperacillin/tazobactam – were developed by ‘penicillin companies’ (Beecham 319 
and Lederle) to extend the utility their products.72 Meanwhile, other 320 
companies developed ‘-lactamase-stable’ cephalosporins. Both approaches 321 
achieved early success, which was eroded over time because (i) the 322 
penicillins, being highly labile, were hard to protect against strains with large 323 
amounts of enzyme, (ii) AmpC enzymes evaded these early inhibitors and (iii) 324 
ESBL-mediated resistance undermined ‘lactamase-stable’ cephalosporins. 325 
One answer – to combine an inhibitor of Class A enzymes with the most-326 
AmpC-stable cephalosporin (cefepime) – was obvious72, but was impossible 327 
in practice because different companies, not interested in collaborating, held 328 
the relevant patents. Cefepime/tazobactam combinations came to be 329 
marketed in India, where trial requirements are less stringent and patent law 330 
weak, but, contained only small amounts of tazobactam (typically 125 mg per 331 
1g of cefepime) and are probably suboptimal.. Only now, facilitated by the US 332 
GAIN (Generating Antibiotic Initiatives Now) Act is high dose (2+2g q8h) 333 
cefepime/tazobactam under development, two decades after it was first 334 
suggested.73,74 335 
In the case of avibactam – the broadest spectrum inhibitor now available – the 336 
decision to partner with ceftazidime was predicated on seeking an 337 
antipseudomonal cephalosporin and on the only viable alternative, cefepime, 338 
being established in fewer markets and, at the time of the decision, subject to 339 
claims – later refuted – of poor efficacy and excess mortality75,76 340 
Aztreonam/avibactam entered development later, predicated on also covering 341 
MBL producers (Table 2).59  342 
Now, with mutational resistance to ceftazidime/avibactam emerging among 343 
isolates with KPC carbapenemase29,30 and aztreonam/avibactam lagging 3 344 
years behind, it is appropriate to reflect these decisions. The mutational 345 
ceftazidime/avibactam resistance entails the KPC enzyme becoming a ‘better’ 346 
ceftazidimase77 and has less effect on other cephalosporin/avibactam 347 
combinations. Might cefepime/avibactam therefore have been a better idea 348 
than ceftazidime/avibactam? Or would it just have selected different mutants? 349 
Since the mutations conferring ceftazidime/avibactam resistance reduce 350 
meropenem resistance (see above), a potential answer is to co-administer 351 
meropenem with ceftazidime/avibactam to block this line of evolution.29,78 352 
Meanwhile, with metallo-carbapenemase producers increasing and 353 
aztreonam/avibactam being unavailable, some doctors are adopting a ‘home 354 
brew’ approach to treat infections due to MBL producers, co-administering 355 
ceftazidime/avibactam with aztreonam - with anecdotal reports of 356 
success.79,80.    Both these strategies – adding meropenem to 357 
ceftazidime/azibactam for infections due to strains with KPC enzymes and 358 
adding aztreonam to ceftazidime/avibactam for those due to MBL producers 359 
are cumbersome ways to partnering avibactam with alternative b-lactams to 360 
ceftazidime, which becomes superfluous in the regimen. 361 
Might not it be better for regulators to require full trials of treatment with a 362 
combination of a new inhibitor with one lactam with then, if these are 363 
successful, to grant restricted licenses for combinations of that inhibitor with 364 
other licensed lactams, based on pharmacodynamic modelling and small 365 
trials demonstrating efficacy against pathogens with relevant resistances? 366 
This would increase flexibility to contend both with current problems and 367 
future Black Swan events. If, for example, the postulated plasmid-borne -368 
lactam-resistant PBP3 were to spread, imipenem-inhibitor combinations would 369 
become more attractive compared with combinations involving PBP3-370 
targetted (i.e. most) -lactams. 371 
In order to prepare for a future certain to contain new Black Swan events, we 372 
also should reflect on vancomycin and colistin. Both were launched in the late 373 
1950s on trials that would be considered wholly unacceptable today. 374 
Vancomycin was licensed for staphylococcal endocarditis on the strength of a 375 
single study involving six patients, complemented by several cases of 376 
compassionate use, together with contention that, with penicillin lost to 377 
resistance, no other agent was effective. Both vancomycin and colistin were 378 
swiftly overtaken by other new agents perceived as less toxic or more 379 
efficacious - methicillin in vancomycin’s case and aminoglycosides and -380 
lactams in colistin’s. For 20 years vancomycin use was minimal.81 Then, with 381 
the rise of MRSA in the 1980s, it found its niche, becoming the mainstay of 382 
treatment. Colistin’s time came later, early in the twenty-first century with the 383 
rise in infections due to carbapenemase-producing Gram-negatives.82 It is 384 
hard to see how either drug would nowadays have been kept on the market 385 
through their long fallow years but it is fortunate that they were. I do not know 386 
the best answer here. Longer patents would increase the chance of ultimate 387 
return on an agent that gained little immediate traction. However, this would 388 
be of little value to a single-product biotech company and, unless restricted to 389 
the immediate product, such patents might stifle development of better 390 
analogues. What is certain is that a strategy of ‘picking winners’ would not 391 
work either– any international body that gave $1 billion prizes to agents that 392 
had failed to find a role for 20 years, and which were perceived to be toxic, 393 
would swiftly be lambasted for wasting taxpayers’ money.  394 
Finally, there is the issue of the issue of non-antibiotic game changers. Just 395 
once in my career a bacterial pathogen posing concerns about resistance–396 
type b Haemophilus influenzae 83– had been essentially eliminated, in this 397 
case by a vaccine. Yet vaccines against tuberculosis, cystitis (and the 398 
ascending E. coli infections it sometimes precipitates), MRSA and gonorrhoea 399 
all remain tantalising possibilities, involving organisms where resistance 400 
presents real and present concerns.84,85 Other non-antibiotic approaches (see 401 
e.g. Czaplewski et al. for a summary)86 may succeed too, though almost all 402 
must be seen as being high risk.    One could not call the success of one of 403 
these approaches a Black Swan event, for it would not arise quite 404 
unexpectedly, but it would have considerable scope to greatly alter projected 405 
numbers of infections and deaths due to antibiotic-resistant bacteria. 406 
Conclusions. 407 
Even with improvements in infection control, stewardship and diagnostics, 408 
resistance will present new challenges. Some, like the emergence of 409 
mutations conferring resistance to ceftazidime/avibactam and 410 
ceftolozane/tazobactam are predictable. Others, involving the escape of ‘new’ 411 
resistance genes, and the spread of these to epidemic strains are Black Swan 412 
events. We know that they will occur; but their future shape, nature and 413 
impact is unpredictable.  414 
 Claims of resistance impact by 2050 should be taken with a very large 415 
pinch of salt but, more than this, we should be wary of believing that we can 416 
predict what the future resistance landscape will look like, let alone use this 417 
for future ‘market entry rewards’. Instead, the best ‘anti-fragile’ strategy to 418 
prepare for an uncertain future lies in diversity, in the hopes that at least one 419 
approach will prove effective not only against problem resistances now 420 
proliferating but also help safeguard against the next Black Swan event. 421 
Rather than having the G20, WHO or whoever, try to pick winners and claim 422 
the ‘market is broken’; international efforts should concentrate on repairing the 423 
market, reducing developmental costs and barriers to entry, thereby pulling in 424 
new players and diverse innovation – regardless of whether this involve 425 
conventional small molecules or non-conventional approaches.  426 
Steps such as the US GAIN Act are to be lauded, as it has encouraged 427 
development of cefepime/tazobactam and the US reappraisal of i.v. 428 
fosfomycin, as is the simplification of trial requirements illustrated by the 429 
development of meropenem-vaborbactam. Yet, more needs to be done, 430 
especially increasing the scope for new combinations of already-licensed 431 
lactams and lactamase inhibitors and to ensure that agents that find little 432 
immediate role become, and remain, available. 433 
Transparency declaration 434 
Advisory Boards or ad-hoc consultancy for Accelerate, Achaogen, Adenium, 435 
Allecra, AstraZeneca, Auspherix, Basilea, BioVersys, Centauri, Discuva, 436 
Integra Holdings, Meiji, Melinta, Nordic, Pfizer, Roche, Shionogi, T.A.Z., 437 
Tetraphase, The Medicines Company, VenatoRx, Wockhardt, Zambon, 438 
Zealand. Paid lectures – Astellas, AstraZeneca, bioMérieux, Beckmann 439 
Coulter, Cardiome, Cepheid, Merck, Pfizer and Nordic. Research funding: 440 
Melinta, Merck, Paratek, Roche, VenatoRx. Relevant shareholdings: Dechra, 441 
GSK, Merck, Perkin Elmer, Pfizer amounting to <10% of portfolio value.  442 
References 443 
1. Anon. Treatment Guidelines for Antimicrobial Use in Common Syndromes (India) 444 
http://icmr.nic.in/guidelines/treatment%20guidelines%20for%20antimicrobial.pdf 445 
2. Neuzillet Y, Naber KG, Schito G et al. French results of the ARESC study: 446 
clinical aspects and epidemiology of antimicrobial resistance in female 447 
patients with cystitis. Implications for empiric therapy. Med Mal Infect 2012; 448 
42: 66-75. 449 
3. Crump JA, Sjölund-Karlsson M, Gordon MA et al. Epidemiology, clinical 450 
presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial 451 
management of invasive Salmonella infections. Clin Microbiol Rev 2015; 28: 452 
901-37.  453 
4. Unemo M, Bradshaw CS, Hocking JS et al. Sexually-transmitted infections: 454 
challenges ahead. Lancet Infect Dis 2017; 17: e235-79. 455 
5. Prasad R, Singh A, Balasubramanian V et al. Extensively drug-resistant 456 
tuberculosis in India: Current evidence on diagnosis and management. Indian 457 
J Med Res 2017; 145: 271-293. 458 
6. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from 459 
here? Clin Microbiol Infect 2004; 10 Suppl 4:18-22. 460 
7. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the 461 
challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.  462 
8. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 463 
71–109. 464 
9. Shlaes DM, Moellering RC. The United States Food and Drug Administration 465 
and the end of antibiotics. Clin Infect Dis 2002; 34: 420–2 466 
10. Finch R; BSAC Working Party on The Urgent Need: regenerating 467 
antibacterial drug discovery and development. Regulatory opportunities to 468 
encourage technology solutions to antibacterial drug resistance. J Antimicrob 469 
Chemother 2011; 66: 1945-7. 470 
11. Sharma P, Towse A. New drugs to tackle antimicrobial resistance: 471 
analysis of EU policy options London, UK: Office of Health Economics; 472 
2011. Available via http://www.ohe.org/publications/article/new-drugs-to-473 
tackle-antimicrobial-resistance-analysis-of-eu-policy-options-21.cfm 474 
12. Livermore DM. Of stewardship, motherhood and apple pie. Int J Antimicrob 475 
Agents 2014; 43: 319-22 476 
13. Livermore DM, Wain J. Revolutionising bacteriology to improve treatment 477 
outcomes and antibiotic stewardship. Infect Chemother 2013; 45: 1-10. 478 
14. Minejima E, Wong-Beringer A. Implementation of rapid diagnostics with 479 
antimicrobial stewardship. Expert Rev Anti Infect Ther 2016; 14: 1065-75. 480 
15. O’Neill J. The Review on Antimicrobial Resistance. Available via https://amr-481 
review.org 482 
16. World Health Organisation. Antimicrobial resistance: global report on 483 
surveillance. Available via 484 
http://www.who.int/drugresistance/documents/surveillancereport/en/ 485 
17. The Pew Charitable Trusts. Antimicrobial Resistance Project 486 
http://www.pewtrusts.org/en/projects/antibiotic-resistance-project 487 
18. Sciarretta K, Røttingen JA, Opalska A et al. Economic incentives for 488 
antibacterial drug development: literature review and considerations from the 489 
Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis 2016; 490 
63:1470-4. 491 
19. Outterson K, Powers JH, Daniel GW et al. Repairing the broken market for 492 
antibiotic innovation. Health Aff (Millwood) 2015; 34: 277-85. 493 
20. Carter D, Charlett A, Conti S et al. A Risk assessment of antibiotic pan-drug 494 
resistance in the UK: Bayesian analysis of an expert elicitation study. 495 
Antibiotics (Basel) 2017; 6 pii: E9. 496 
21. Lowenstein R. When Genius Failed. New York: Random House, 2000 497 
22. Taleb NN. The Black Swan. New York: Random House , 2007 498 
23. Anon. What we know about 'unknown unknowns' 499 
http://news.bbc.co.uk/1/hi/magazine/7121136.stm 500 
24. Woodford N, Ellington MJ. The emergence of antibiotic resistance by 501 
mutation. Clin Microbiol Infect 2007; 13: 5-18. 502 
25. Livermore DM. Clinical significance of -lactamase induction and stable 503 
derepression in Gram-negative rods. Eur J Clin Microbiol 1987; 6: 439-45. 504 
26. Kaye KS, Cosgrove S, Harris A et al. Risk factors for emergence of 505 
resistance to broad-spectrum cephalosporins among Enterobacter spp. 506 
Antimicrob Agents Chemother 2001; 45: 2628-30 507 
27. Lynch MJ, Drusano GL, Mobley HL. Emergence of resistance to imipenem in 508 
Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987; 31: 1892-6. 509 
28. O’Dwyer K, Spivak AT, Ingraham K et al. Bacterial resistance to leucyl-tRNA 510 
synthetase inhibitor GSK2251052 develops during treatment of complicated 511 
urinary tract infections. Antimicrob Agents Chemother 2015; 59: 289–298. 512 
29. Livermore DM, Warner M, Jamrozy D et al. In vitro selection of 513 
ceftazidime/avibactam resistance in Enterobacteriaceae with KPC-3 514 
carbapenemase. Antimicrob Agents Chemother 2015; 59: 5324-30. 515 
30.  Shields RK, Potoski BA, Haidar G et al. Clinical outcomes, drug toxicity, and 516 
emergence of ceftazidime/avibactam resistance among patients treated for 517 
carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 518 
63:1615-8. 519 
31. MacVane SH, Pandey R, Steed LL et al. Emergence of 520 
ceftolozane/tazobactam-resistant Pseudomonas aeruginosa during treatment 521 
is mediated by a single AmpC structural mutation. Antimicrob Agents 522 
Chemother 2017; 61 pii: e01183-17.  523 
32. Fraile-Ribot PA, Cabot G, Mulet X et al. Mechanisms leading to in vivo 524 
ceftolozane/tazobactam resistance development during the treatment of 525 
infections caused by MDR Pseudomonas aeruginosa. J Antimicrob 526 
Chemother 2017 Nov 14. doi: 10.1093/jac/dkx424. 527 
33. Tsubakishita S, Kuwahara-Arai K, Sasaki T et al. Origin and molecular 528 
evolution of the determinant of methicillin resistance in staphylococci. 529 
Antimicrob Agents Chemother 2010; 54: 4352-9.  530 
34. Cantón R. Antibiotic resistance genes from the environment: a 531 
perspective through newly identified antibiotic resistance mechanisms 532 
in the clinical setting. Clin Microbiol Infect. 2009; 15 Suppl 1: 20-5.  533 
35. Poirel L, Kieffer N, Fernandez-Garayzabal JF et al. MCR-2-mediated 534 
plasmid-borne polymyxin resistance most likely originates from 535 
Moraxella pluranimalium. J Antimicrob Chemother 2017; 72: 2947-9. 536 
36. Matthew M. Plasmid-mediated -lactamases of Gram-negative 537 
bacteria: properties and distribution. J Antimicrob Chemother 1979; 5: 538 
349-58. 539 
37. Schmitt R. Molecular biology of transposable elements. J Antimicrob 540 
Chemother 1986; 18 Suppl C: 25-34. 541 
38.  Nicolas E, Lambin M, Dandoy D et al. The Tn3-family of replicative 542 
transposons. Microbiol Spectr.2015; 3: doi: 543 
10.1128/microbiolspec.MDNA3-0060-2014. 544 
39.  Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 545 
2012; 39: 283-94. 546 
40.  Livermore DM, Hope R, Reynolds R et al. Declining cephalosporin and 547 
fluoroquinolone non-susceptibility among bloodstream 548 
Enterobacteriaceae from the UK: links to prescribing change? J 549 
Antimicrob Chemother 2013; 68: 2667-74. 550 
41. Liu PY, Gur D, Hall LM et al. Survey of the prevalence of -lactamases 551 
amongst 1000 gram-negative bacilli isolated consecutively at the Royal 552 
London Hospital. J Antimicrob Chemother 1992; 30: 429-47. 553 
42. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the 554 
face of ESBLs in Europe. J Antimicrob Chemother 2007; 59:165-74. 555 
43. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, 556 
an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543-74. 557 
44. Ciesielczuk H, Doumith M, Hope R et al. Characterization of the extra-558 
intestinal pathogenic Escherichia coli ST131 clone among isolates 559 
recovered from urinary and bloodstream infections in the United 560 
Kingdom. J Med Microbiol 2015; 64:1496-503. 561 
45. Clark C. The Sleepwalkers: How Europe Went to War in 1914. 562 
London: Allen Lane, 2013. 563 
46. D'Costa VM, McGrann KM, Hughes DW et al. Sampling the antibiotic 564 
resistome. Science 2006; 311: 374-7.  565 
47.  D'Costa VM, Mukhtar TA, Patel T et al. Inactivation of the lipopeptide 566 
antibiotic daptomycin by hydrolytic mechanisms. Antimicrob Agents 567 
Chemother 2012; 56: 757-64.  568 
48. Shaw KJ, Rather PN, Hare RS et al. Molecular genetics of 569 
aminoglycoside resistance genes and familial relationships of the 570 
aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138-63. 571 
49. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside Resistance: The 572 
Emergence of acquired 16S ribosomal RNA methyltransferases. Infect 573 
Dis Clin North Am 2016; 30: 523-37. 574 
50. Patel R, Piper K, Cockerill FR et al. The biopesticide Paenibacillus 575 
popilliae has a vancomycin resistance gene cluster homologous to the 576 
enterococcal VanA vancomycin resistance gene cluster. Antimicrob 577 
Agents Chemother 2000; 44: 705-9. 578 
51. Guardabassi L, Perichon B, van Heijenoort J et al. Glycopeptide 579 
resistance vanA operons in Paenibacillus strains isolated from soil. 580 
Antimicrob Agents Chemother 2005; 49: 4227-33. 581 
52. Berger-Bächi B. Genetic basis of methicillin resistance in 582 
Staphylococcus aureus. Cell Mol Life Sci 1999; 56: 764-70. 583 
53. Curtis NA, Orr D, Ross GW et al. Affinities of penicillins and 584 
cephalosporins for the penicillin-binding proteins of Escherichia coli K-585 
12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 586 
16: 533-9. 587 
54. Hashizume T, Ishino F, Nakagawa J et al. Studies on the mechanism 588 
of action of imipenem (N-formimidoylthienamycin) in vitro: binding to 589 
the penicillin-binding proteins (PBPs) in Escherichia coli and 590 
Pseudomonas aeruginosa, and inhibition of enzyme activities due to 591 
the PBPs in E. coli. J Antibiot (Tokyo) 1984; 37: 394-400. 592 
55. Beesley L. The Loss of the SS Titanic: its Story and Lessons. Boston 593 
and New York: Houghton Mifflin, 1912. 594 
56. Philippon A, Labia R, Jacoby G. Extended-spectrum -lactamases. 595 
Antimicrob Agents Chemother 1989; 33: 1131-6 596 
57. Watanabe M, Iyobe S, Inoue M et al. Transferable imipenem resistance 597 
in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 598 
147-51. 599 
58. Johnson AP, Woodford N. Global spread of antibiotic resistance: the 600 
example of New Delhi metallo-β-lactamase (NDM)-mediated 601 
carbapenem resistance. J Med Microbiol 2013; 62: 499-513. 602 
59. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 603 
combinations with ceftazidime and aztreonam against carbapenemase-604 
producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 605 
55: 390-4.  606 
60. Livermore DM, Mushtaq S, Warner M et al. In vitro activity of 607 
cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J 608 
Antimicrob Chemother 2017; 72: 1373-85. 609 
61. Livermore DM, Warner M, Mushtaq S et al. Interactions of OP0595, a 610 
novel triple-action diazabicyclooctane, with β-lactams against OP0595-611 
resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 612 
2015; 60: 554-60. 613 
62.  Morinaka A, Tsutsumi Y, Yamada M et al. OP0595, a new 614 
diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, 615 
antibiotic and β-lactam 'enhancer'. J Antimicrob Chemother 2015; 70: 616 
2779-86. 617 
63. Mushtaq S, Vickers A, Woodford N et al. Nacubactam (RG6080) alone and in 618 
combination against metallo--lactamase (MBL)-producing 619 
Enterobacteriaceae. In Abstracts of the Twenty-eighth European Conference 620 
on Clinical Microbiology and Infectious Diseases, Madrid 21-24 April 2018, 621 
Abstract 604. 622 
64. World Health Organisation. Antibacterial Agents in Clinical 623 
Development. Available via 624 
http://www.who.int/medicines/news/2017/IAU_AntibacterialAgentsClinic625 
alDevelopment_webfinal_2017_09_19.pdf 626 
65. Mushtaq S, Vickers A, Woodford N et al. Potentiation of cefepime by the 627 
boronate VNRX-5133 vs. Gram-negative bacteria with known -lactamases. 628 
In Abstracts of the Twenty-eighth European Conference on Clinical 629 
Microbiology and Infectious Diseases, Madrid 21-24 April 2018, Abstract 650. 630 
66. Kohira N, West J, Ito A et al. In vitro antimicrobial activity of a 631 
siderophore cephalosporin, S-649266, against Enterobacteriaceae 632 
clinical isolates, including carbapenem-resistant strains. Antimicrob 633 
Agents Chemother 2015; 60: 729-34. 634 
67. Reck F, Bermingham A, Blais J et al. Optimization of novel 635 
monobactams with activity against carbapenem-resistant 636 
Enterobacteriaceae -Identification of LYS228. Bioorg Med Chem Lett 637 
2018 Jan 4. pii: S0960-894X(18)30006-4. 638 
68. Shlaes D.M. The Clinical Development of Antibacterial Drugs: A Guide 639 
for the Discovery Scientist. In: Topics in Medicinal Chemistry pp1-15. 640 
Berlin, Heidelberg: Springer, 2017. 641 
69.  Qin X, Tran BG, Kim MJ et al. A randomised, double-blind, phase 3 642 
study comparing the efficacy and safety of ceftazidime/avibactam plus 643 
metronidazole versus meropenem for complicated intra-abdominal 644 
infections in hospitalised adults in Asia. Int J Antimicrob Agents 2017; 645 
49: 579-88.  646 
70.  Stone GG, Bradford PA, Yates K et al. In vitro activity of ceftazidime/ 647 
avibactam against urinary isolates from patients in a phase 3 clinical 648 
trial programme for the treatment of complicated urinary tract 649 
infections. J Antimicrob Chemother 2017; 72: 1396-9.  650 
71. Carmeli Y, Armstrong J, Laud PJ et al. Ceftazidime/avibactam or best 651 
available therapy in patients with ceftazidime-resistant 652 
Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary 653 
tract infections or complicated intra-abdominal infections (REPRISE): a 654 
randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 655 
16: 661-73. 656 
72. Livermore DM, Hope R, Mushtaq S et al. Orthodox and unorthodox 657 
clavulanate combinations against extended-spectrum -lactamase 658 
producers. Clin Microbiol Infect 2008; 14 Suppl 1:189-93. 659 
73. Sader HS, Castanheira M, Mendes RE et al. Antimicrobial activity of 660 
high-proportion cefepime/tazobactam (WCK 4282) against a large 661 
number of Gram-negative isolates collected worldwide in 2014. 662 
Antimicrob Agents Chemother 2017; 61pii: e02409-16.  663 
74.  Livermore DM, Mushtaq S, Warner M et al. Potential of high-dose 664 
cefepime/tazobactam against multiresistant Gram-negative pathogens. 665 
J Antimicrob Chemother 2018; 73: 126-33. 666 
75. Yahav D, Paul M, Fraser A et al. Efficacy and safety of cefepime: a 667 
systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 338-668 
48. 669 
76. Kim PW, Wu YT, Cooper C et al. Meta-analysis of a possible signal of 670 
increased mortality associated with cefepime use. Clin Infect Dis 2010; 671 
51: 381-9. 672 
77. Barnes MD, Winkler ML, Taracila MA et al. Klebsiella pneumoniae 673 
carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, 674 
and resistance to ceftazidime/avibactam: unique antibiotic-resistant 675 
phenotypes emerge from β-lactamase protein engineering. MBio 2017; 676 
8 pii: e00528-17. 677 
78. Livermore DM, Meunier D, Hopkins KL et al. Activity of 678 
ceftazidime/avibactam against problem Enterobacteriaceae and 679 
Pseudomonas aeruginosa in the UK, 2015-16. J Antimicrob Chemother 680 
2017 Dec 8. doi: 10.1093/jac/dkx438. 681 
79. Mojica MF, Ouellette CP, Leber A et al. Successful treatment of 682 
bloodstream infection due to metallo-β-lactamase-producing 683 
Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob 684 
Agents Chemother 2016; 60: 5130-4.  685 
80. Davido B, Fellous L, Lawrence C et al. Ceftazidime/avibactam and 686 
aztreonam, an interesting strategy to overcome β-lactam resistance 687 
conferred by metallo-β-lactamases in Enterobacteriaceae and 688 
Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61. 689 
pii: e01008-17. 690 
81. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of 691 
vancomycin. Antimicrob Agents Chemother 1998; 42: 1303-4. 692 
82. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in 693 
patients with ICU-acquired infections caused by multiresistant Gram-694 
negative bacteria: the renaissance of an old antibiotic. Clin Microbiol 695 
Infect 2005; 11: 115-21 696 
83. Jordens JZ, Slack MP. Haemophilus influenzae: then and now. Eur J 697 
Clin Microbiol Infect Dis 1995; 14: 935-48. 698 
84. Clift C, Salisbury DM. Enhancing the role of vaccines in combatting 699 
antimicrobial resistance. Vaccine 2017; 35: 6591-3.  700 
85. Huttner A, Hatz C, van den Dobbelsteen G et al. Safety, 701 
immunogenicity, and preliminary clinical efficacy of a vaccine against 702 
extraintestinal pathogenic Escherichia coli in women with a history of 703 
recurrent urinary tract infection: a randomised, single-blind, placebo-704 
controlled phase 1b trial. Lancet Infect Dis 2017; 17: 528-37. 705 
86. Czaplewski L, Bax R, Clokie M et al. Alternatives to antibiotics-a 706 
pipeline portfolio review. Lancet Infect Dis 2016; 16: 239-51. 707 
708 




Reached Source Antibiotics 
affected 
mecA S. aureus S. fleurettii -Lactams 







All groups Streptomyces Aminoglycosides 









blaOXA-23 A. baumannii A. radioresistens -Lactams 
including 
carbapenems 






Data are from references 33-35 711 
mcr-1
 
Enterobacteriaceae Moraxella Polymyxins 
qnr Enterobacteriaceae Shewanella  Fluoroquinolones 
Table 2. Developmental -lactams and -lactamase inhibitor combinations active against MBL producers 
 






Aztreonam is stable to 
MBLs; avibactam protects 
against co-producer 
ESBLs and AmpC 
enzymes  
Weak antipseudomonal 






Zidebactam has direct 
antibacterial activity and, 
although it does not inhibit 
MBLs, it achieves synergy 
with cefepime by an 
High frequency of mutational 
resistance to zidebactam, 
though this does not 
compromise the enhancer 
effect. 
Unknown 
‘enhancer effect’ reflecting 
attack on different PBPs.  
Meropenem/nacubactam61,62,63 Carbapenem/DBO 
(Roche) 
Nacubactam has direct 
antibacterial activity and, 
although it does not inhibit 
MBLs, it achieves synergy 
with meropenem by an 
‘enhancer effect’ reflecting 
attack on different PBPs. 
As cefepime/zidebactam, 
but generally slightly less 
active, particularly against P. 
aeruginosa; enhancer effect 




VNRX-5133 is a second 
generation boronate 
which, unlike 
vaborbactam, also inhibits 
MBLs and OXA-48 
Inhibits VIM and NDM 
enzymes, but not IMP. MICs 
for some NDM producers 
remain around 8 mg/L, even 
with a 1:1 combination. 
Unknown 
Cefiderocol66 Catechol cephalosporin 
(Shionogi) 
 
As a catechol, cefiderocol 
is efficiently taken into 
bacteria via the iron-
uptake pathway. It is also 
near stable to most 
relevant -lactamase, 
including MBLs 
MICs for NDM producers, 
though mostly only 2-4 
mg/L, are raised compared 
to those for bacteria with 
other MBLs. Long history of 
development problems with 
catechol -lactams raises 
concern, though cefiderocol 
seems to evade these. Not 
clear if bacteria might 
develop resistance by 
switching to other iron 
uptake routes. 
Unknown 
LYS-22867 Monobactam Monobactams are stable Early stage; not active Unknown 
(Novartis) to MBLs; this has also 
been engineered to be 
stable to ESBLs, AmpC 
enzymes, OXA-48 and 
KPC types 
against P. aeruginosa 
 
  
Figure 1 legend 
Trajectory of oxyimino-cephalosporin (cefotaxime/ceftazidime) resistance in bloodstream E. coli in the UK excluding Scotland. From 
1990-2000 there was considerable exposure to cephalosporins but little or no accumulation of resistance. The sharp rise from 
2002-2006/7 then reflects the emergence (or introduction) of ST131 E. coli with CTX-M ESBLs and their proliferation. Updated from 
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